A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Sitravatinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Mirati Therapeutics
- 15 Oct 2019 Planned End Date changed from 1 Dec 2019 to 1 Apr 2020.
- 15 Oct 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Feb 2020.
- 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium